Ljósmæðrablaðið - 15.04.2002, Blaðsíða 17

spurningin: “Hverjum á að bjóða skimun fyrir
litningagöllum fósturs?” Ef litið er til alþjóðlegra
samþykkta ífá Alþjóða Heilbrigðismálastofhuninni
(25) og Evrópuráðinu varðandi skimun á meðgöngu
kemur skýrt fram sú skoðun að stjórnvöld skuli
tryggja jafnt aðgengi allra þeirra sem óska
þjónustunnar (26,27). Lögð er áhersla á að
þjónustan skuli vera valkostur en ekki skylda og
að góð fræðsla og ráðgjöf sé nauðsynleg fyrir og
eftir prófun. Að mínu mati getur enginn
heilbrigðisstarfsmaður eða stofnun tekið sér það
vald að segja fólki fyrir verkum, en nauðsynlegt
er að heilbrigðisstarfsmenn ffæði verðandi foreldra
svo þau geti sjálf tekið upplýsta ákvörðun varðandi
fósturskimun á grundvelli persónulegra skoðana
og aðstæðna.
Heimildaskrá
1 .Merkalz IR Nitow.'sky HM, Macri JN eLal., An association between
low maternal serum alpha-fetoprotein and fetal chromosomal
abnormalities. Am J Obstet Gynecol 1984:148:866.
2. Wald NJ, Cuckle HS, Densen JW et.al., Maternal serum
unconjugated estriol as an antenatal screening test for Down syndrome.
BrJ Obstet Gynaecol 1988:95:334.
3. Cuckle HS, Wbld NJ. HCG, estriol and other matemal bood markers
of fetal aneuploidy. In Elias S, Simpson JL (eds.) Maternal serum
screening for fetal genetíc disorders. New\brk, Chutchill Livingstone,
1992, p. 87.
4. Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA,
Johnson A. Saeening of matemal serum for fetal Down's syndrome
in the first trimester. N Engl J Med 1998:338:955.
5. Spencer K, Souter V Tul N, Snijders RJM, Nicolaides KH. A
screening program for trisomy 21 at 10-14 weeks using fetal nuchal
translucency, matemal serum free b-human chorionic gonadotropin .
and pregnancy- associated plasma protein A. Ultrasound Obstet
Gynecol 1999:13:231.
6. Snijders RM, Noble P, Sebire N, Souka A, Nicolaides KH. UK
multicentre project on assessment of risk of trisomy 21 by matemal
age and fetal nuchal translucency thickness at 10-14 weeks of gestatíoa
Lancet 1998:352.343.
7. VonKaisenberg CS, Krenn V Ludwig M, Nicolaides KH, Brand-
Saberi B. Morphological classificatíon of nuchal skin in fetuses with
trisony 21,18 and 13 at 12-18 weeks and in a trisomy 16 mouse.
Anat Embtyol 1998;197:105-24.
8. Chitayat D, Kalousek DK, Bamforth JS. Lymphatíc abnormalities
in fetuses with posterior cervical cystíc hygroma. Am J Med Genet
1989:33:352.
9. Phibbs RH, Johnson P, Tooley WH. Cardiorespiratory status of
eiythroblastotic infants: II. Blood volume, hematocrit and semm
albumin concentrations in relation to lydrops fetalis. Pediatrics
1974:53:13.
10. Petrikovsky BM, Baker D, Schneider E. Fetal hydrops secondaty
to human parvovirus infection in early pregnancy. Prenat Diagn
1996:16:342.
11. Whitlow BJ, Economides DL. The optimal gestational age
to examine fetal anatomy and measure nuchal translucency in the
first trimester. Ultrasound Obstet Gynecol 1998:11:258.
12. Pandya PR Altman D, Brizot ML, Pettersen H, Nicolaides KH.
Repeatability of measurement of fetal nuchal translucency thickness.
Ultrasound Obstet Gynecol 1995:5:334.
13. Wald NJ, Leck I, eds. Antenatal and Neonatal Screening, 2nd ed„
Oxford University Press, 2000:1,2,23.
14. Torfadóttir G, Jónsson JJ. Lífefnaskimun fyrir fósturgöllum.
Læknablaðið 2001:87:431.
15. Spencer K, Spencer CE, Power M, Moakes A, Nicolaides KH.
One stop dinic for assessment of risk for fetal anomalies: a report of
the first year of prospective screening for chromosomal anomalies
in the first trimester. Br J Obstet Gynaecol 2000:107:1271.
16. Dunstan FDJ, Nbt ABJ. Screening for Down's syndrome; the
effect oftest date on the detection rate. Ann Clin Biochem 1999:35:57.
17. Wald NJ, Kennard A, Hackshaw A, McGuire AI. Antenatal
screening for Down's syndrome. J Med Screen 1997:4:181.
18. Hyett JA, Perdu M, Sharland GK, Snijders RJM, Nicolaides KH.
Increasednuchaltranslucencyat 10-14 wœksofgestationasamarker
formajorcardiacdefects. Uitrasound Obstet Gynecol 1997:10:242.
19. Souka AR Snijders RJM, Novakov A, Soares W Nicolaides KH.
Defects and syndromes in chromosomally normal fetuses with
increased nuchal translucency thickness at 10-14 vœeks of gestatíon.
Ultrasound Obstet Gynecol 1997:11:391.
20. Hyett JA, Perdu M, Sharland GK, Snijders RJM, Nicolaides KH.
Using fetal nuchal translucency to screen for major congenital cardiac
defects at 10-14 weeks of gestatíon: population based cohort study.
BrMedJ 1999:318:81.
21. Ville Y, Lalondrelle C, Doumerc S, Daffos F, Fiydman R, Outy
JF, DumezY Rrst trimester diagnosis of nuchal anomalies. significanœ
and fetal outcome. Ultrasound Obstet Gynecol 1992:2:314.
22. Sebire NJ, Snijders RJM, Davenport M, GreenoughA, Nicolaides
KH. Fetalnuchaltranslucenty thicknessat 10-14weeksofgestation
and congenital diaphragmatic hemia. Obstet Gyneod 1997:90:943.
23. FukadaY,YasumizuT,TakizawaM, AmemiyaA, Hoshi K. The
prognosis of fetuses with transient nuchal translucency in the first
andearlysecondtrimester. Acta Obstet Gynecol Scand 1998:76:913.
24. Salvesen KA, Öyen L, Schmidt N, Malt UF, Eik-Nes SH.
Comparison of long-term psychological responses of women after
pregnancy termination due to fetal anomalies and afier perinatal loss.
Ultrasound ObstGynecol 1997:9:80.
25. Proposed intematíonal Guidelines on Ethical issues in Medical
genetics and Genetic Services, Report of a WHO Meeting on Ethical
Issues in Medical Genetics , Genevea, 15-16 December 1997.
http://www.who.int/ncd/hgn/hgnethic.htm
26. Tilmæli Ráðherranefhdarinnar R (90) 13 til aðildarríkja varðandi
forburðarskimun, forburðarerfðagreiningu og erfðaráðgjöf þeim
tengda. http://cm.coe.int/ta/rec/1990/90rl3.htm.
27. Ályktun Ráðherranefhdarinnar R (92) 3 til aðildarrikjanna um
erfðaprófanir og erfðaskimun í heilbrigðisskyni.
http://cm.coe.int/ta/rec/1992/92r3.htm.